Stammdaten
eFFECTOR Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of selective translation regulator inhibitors for the treatment of cancer. Its lead product candidate is Tomivosertib, an oral small-molecule inhibitor of MNK that is in phase 2b clinical trial for the treatment of patients with metastatic non-small cell lung cancer. The company is also developing Zotatifin, a small molecule designed to inhibit eukaryotic initiation factor 4A (eIF4E), which is in phase 2clinical trial to treat patients with solid tumors. It has a collaboration agreement with Pfizer Inc. to develop inhibitors of eIF4E. eFFECTOR Therapeutics, Inc. was founded in 2012 and is headquartered in Solana Beach, California.
Unternehmen & Branche
| Name | eFFECTOR Therapeutics, Inc. |
|---|---|
| Ticker | EFTR |
| CIK | 0001828522 |
| Boerse | US |
| Sektor | Healthcare |
| Industrie | Biotechnology |
| SIC | 2834 · Pharmaceutical Preparations |
Wertpapier & Kennzahlen
| CUSIP | – |
|---|---|
| ISIN | – |
| Typ | Common Stock |
| Marktkapitalisierung | 941 USD |
| Beta | 0,89 |
| Dividendenrendite | 0,00 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2024-03-31 | 10-Q | 0 | -8,834,000 | -2.16 | 27,131,000 | 827,000 |
| 2023-12-31 | 10-K | 0 | -35,811,000 | -16.37 | 20,544,000 | -5,795,000 |
| 2023-09-30 | 10-Q | 0 | -8,303,000 | -0.13 | 20,161,000 | -3,966,000 |
| 2023-06-30 | 10-Q | 0 | -8,364,000 | -0.17 | 26,889,000 | 2,575,000 |
| 2023-03-31 | 10-Q | 0 | -10,014,000 | -5.96 | 21,928,000 | -4,813,000 |
| 2022-12-31 | 10-K | 3,553,000 | -22,665,000 | -13.76 | 29,077,000 | 3,896,000 |
| 2022-09-30 | 10-Q | 867,000 | -9,559,000 | -0.23 | 36,651,000 | 11,560,000 |
| 2022-06-30 | 10-Q | 2,011,000 | -6,915,000 | -0.17 | 43,471,000 | 19,623,000 |
| 2022-03-31 | 10-Q | 0 | 3,069,000 | 0.07 | 49,495,000 | 25,234,000 |
| 2021-12-31 | 10-K | 1,430,000 | 15,798,000 | 0.44 | 54,056,000 | 17,284,000 |
| 2021-09-30 | 10-Q | 427,000 | 8,879,000 | 0.42 | 59,936,000 | -7,669,000 |
| 2021-06-30 | 10-Q | 692,000 | -5,548,000 | -3.83 | 176,440,824 | -144,011,000 |
| 2021-03-31 | 10-Q | 0 | -6,582,000 | -4.55 | 176,816,736 | -138,639,000 |
| 2020-12-31 | 10-K | 42,000,000 | 14,211,000 | 0.11 | 16,704,000 | -132,245,000 |
| 2020-12-31 | 10-Q | -5,854,000 | 16,704,000 | -132,245,000 | ||
| 2020-09-30 | 10-Q | 574,000 | -7,609,000 | -5.29 | -126,546,000 | |
| 2020-06-30 | 10-Q | 8,593,000 | -119,113,000 | |||
| 2020-03-31 | 10-Q | 19,081,000 | -127,877,000 |
Fondsaktivität (Vorquartalsvergleich)
Insider-Transaktionen (12 Monate)
Top-Fondshalter
Keine Fondsdaten zu dieser Aktie vorhanden.